- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04834037
Effect of Provision of Information and Supportive Nursing Care: A Randomised Controlled Trial
The Effect of Provision of Information and Supportive Nursing Care on Blood Gas, Vital Signs, Anxiety, Stress and Agitation Levels in COPD Patients Treated With NIV: A Randomised Controlled Trial
Background: Informative and supportive nursing care is essential to reduce complications and improve outcomes in Chronic Obstructive Pulmonary Disease (COPD) patients treated with Non-Invasive Ventilation (NIV).
Objective: Aim of the study is to determine the effect of provision of information and supportive nursing care on blood gas, vital signs, anxiety, stress and agitation levels in COPD patients treated with NIV.
Research Methodology: A randomised controlled design was used between September-December 2019. The universe of the study consisted of COPD patients treated with NIV in intensive care unit in a state hospital. A total of 60 patients, composed of 30 interventions and 30 controls, were randomly included in the sample. Provision of information and supportive nursing care was applied to the patients in the intervention group. The data were evaluated with SPSS program.
Results: Following the intervention, the findings showed that the provision of information and supportive nursing care has a positive effect on the blood gas, vital signs, anxiety, stress and agitation levels of patients.
Conclusions: The provision of information and supportive nursing care is recommended to alleviate anxiety, stress and agitation in COPD patients treated with NIV
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Trial design and the participants A randomised controlled design was used between September-December 2019. This study has been approved (B.30.2.ODM.0.20.08/390) by an ethics committee. In order to carry out the study, an application permit (17186359-604.02) was obtained from the Provincial Health Directorate and the relevant hospital. In addition, written consent forms were obtained from all the patients.
The sample size was determined using G * Power 3.1 software since there was no pilot data. According to the power analysis, the number of the participants was calculated as at least 54 when a type 1 error was taken as 0.05, power as 0.95, and the effect size as moderate (0.25) for two groups design with two repeated measures. In order to prevent possible data loss, the volume of the sample was increased by 10% and the total number of the participants was determined as 60. A total of 60 COPD patients treated with NIV in intensive care unit, composed of 30 interventions and 30 controls, were randomly included in the sample. Provision of information and supportive nursing care was applied to the patients in the intervention group while the control group received routine nursing care. The inclusion criteria for participants were: (a) a diagnosis of COPD (b) treated with NIV (c) be conscious of (d) agreement to participate in the study and (e) COPD patients starting NIV therapy for the first time. Patients who were intubated and therefore unable to speak, received sedation and had a Glaskow Coma Scale score below 14 were excluded. There was no drop-out during the study.
Data collection tools Personal Information Form: The form, developed by the researchers, included questions about age, gender, educational level, marital status, smoking, information on COPD, nausea and vomiting, information on NIV use.
Depression Anxiety Stress Scale (DASS-21): The scale was first developed by Lovibond and Lovibond (1995) with 42 items and three sub-dimensions. It was later revised to 21 items in 1997. The scale is 4-point Likert type, consists of 21 items and 3 sub-dimensions (depression, anxiety, stress). The adaptation of the scale to Turkish and its validity and reliability studies were conducted. Evaluation is obtained by summing the scores given to the items it contains for each sub-dimension. Minimum 0 and maximum 21 points can be obtained in all dimensions. The subscales of the scale are Cronbach's alpha values; depression 0.81, anxiety 0.80, stress 0.75.
Richmond Agitation-Sedation Scale (RASS): RASS scale was developed by a multidisciplinary team at Virginia Common Wealth University. RASS is a 10-point scale that is evaluated using verbal stimulation followed by eye contact, which is not available in other scales. It is proven that RASS has excellent validation compared to a wide range of visual analog scales and selected sedation measurements for adult medical and surgical intensive care patients. While zero (0) points on the scale indicate the ideal level, it reflects the increasing agitation towards the (+4) level and the decreasing sedation level to the (-5) level. Since patients receiving sedation were not included in this study, only the agitation dimension of the RASS scale was used.
Glaskow Coma Scale (GCS): It was developed in Scotland / Glasgow in 1974 to describe the consciousness level of patients. The scale is widely used to assess patients' level of consciousness. There are 3 separate sections in the scale: eye opening, verbal and motor response. GCS is obtained by summing the points the patient gets from each section. This score ranges from three (3) to fifteen (15). If the GCS total score is 13-15, the patient is considered awake, between 8-12 as precoma, and below 8 as coma.
Intervention Patients in the experimental group were provided with information in addition to routine nursing care and supportive care interventions were made. The information leaflet was explained to the patients in the experimental group face to face by the researchers and the information was repeated according to the patient's needs. Supportive nursing care was also practiced to the patients in the experimental group by the researchers. Routine nursing care was practiced to the control group in the intensive care clinic where the patients were located.
As a pre-test measure, blood gases were taken from the patients in the experimental and control groups, their vital signs were measured, their state of consciousness was evaluated, and DASS-21 (anxiety and stress sub-dimension) and RASS (agitation dimension) were practiced by face-to-face interviews with the patients. As the last test, the same measurements were made 5 days after the first measurement and before the patients were transferred to the normal service.
An information pamphlet consisting of textual material about NIV treatment was developed. The content of the information leaflet consisted of topics that will facilitate patient compliance to treatment, such as the introduction of equipment used in NIV treatment, the intended use of NIV and its effects on the patient, what patients generally experience during treatment, compliance problems in NIV, how the procedure will be performed, each procedure the nurse will do and for what purpose, the duration of the treatment, what the patient can and cannot do during the treatment, what kind of process will proceed if everything goes well. As supportive care, patients were allowed to express their feelings and thoughts about NIV treatment, an accepting and empathetic approach was shown to the patients, care was taken to make eye contact while communicating, therapeutic touch technique was used, it was explained how the patients could reach the nurse when needed, the environment was arranged, each procedure performed was explained with its objectives, they were placed in a position where they could see the clock, strategies that will make it easier for the patients to cope during the treatment were determined and they were encouraged to do so (for example, some patients wanted to read a book and some patients wanted to sleep), the patients were encouraged to ask questions comfortably, it was stated that the treatment could be interrupted for a while when they felt bad due to the mask, and it was ensured that the patients met with their relatives during the visiting hours.
Data analysis The Statistical Package for Social Sciences (SPSS) 20.0 package program was used in the analysis of the data. Descriptive statistics were used as mean ± standard deviation for variables with normal distribution, and median (min - max) for variables with non-normal distribution. Nominal variables were shown as the number of patients (n) and (%). The compliance of the data to normal distribution was examined with the Shapiro-Wilk test and the homogeneity of the variances with the Levene test. For the comparison of the experimental and control groups, Student's T test was used for data with normal distribution, Mann Whitney U test was used for data with non-normal distribution. Chi-Square and Fisher's Exact tests were used for group comparisons of nominal variables. "Analysis of Variance in Repeated Measures" was used to analyze the values of the experimental and control groups before and after the training in order to evaluate the effectiveness of the provision of information and supportive nursing care intervention practised to the experimental group. In the analysis of all tests, p value <0.05 was considered statistically significant.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Samsun, Turkey
- Bafra State Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- a diagnosis of COPD treated with NIV be conscious of agreement to participate in the study COPD patients starting NIV therapy for the first time
Exclusion Criteria:
- intubated therefore unable to speak received sedation had a Glaskow Coma Scale score below 14 were excluded
Study Plan
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: RANDOMIZED
- Interventional Model: SINGLE_GROUP
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Experimental
Patients in the experimental group were provided with information in addition to routine nursing care and supportive care interventions were made. The information leaflet was explained to the patients in the experimental group face to face by the researchers and the information was repeated according to the patient's needs. As a pre-test measure, blood gases were taken from the patients in the experimental and control groups, their vital signs were measured, their state of consciousness was evaluated, and DASS-21 (anxiety and stress sub-dimension) and RASS (agitation dimension) were practiced by face-to-face interviews with the patients. As the last test, the same measurements were made 5 days after the first measurement and before the patients were transferred to the normal service. An information pamphlet consisting of textual material about NIV treatment was developed. |
The provision of information and supportive nursing care is recommended to alleviate anxiety, stress and agitation in COPD patients treated with NIV.
|
NO_INTERVENTION: No intervention
Routine nursing care was practiced to the control group in the intensive care clinic where the patients were located.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Depression Anxiety Stress Scale (DASS-21)
Time Frame: 3 months
|
The scale was first developed by Lovibond and Lovibond (1995) with 42 items and three sub-dimensions.
It was later revised to 21 items by Brown et al. (1997) in 1997.
The scale is 4-point Likert type, consists of 21 items and 3 sub-dimensions (depression, anxiety, stress).
The adaptation of the scale to Turkish and its validity and reliability studies were conducted by Yılmaz et al. (2017).
Evaluation is obtained by summing the scores given to the items it contains for each sub-dimension.
Minimum 0 and maximum 21 points can be obtained in all dimensions.
The subscales of the scale are Cronbach's alpha values; depression 0.81, anxiety 0.80, stress 0.75 (Yılmaz et al., 2017).
|
3 months
|
Richmond Agitation-Sedation Scale (RASS)
Time Frame: 3 months
|
RASS scale was developed by a multidisciplinary team at Virginia Common Wealth University (Sessler et al. , 2002).
RASS is a 10-point scale that is evaluated using verbal stimulation followed by eye contact, which is not available in other scales.
It is proven that RASS has excellent validation compared to a wide range of visual analog scales and selected sedation measurements for adult medical and surgical intensive care patients.
While zero (0) points on the scale indicate the ideal level, it reflects the increasing agitation towards the (+4) level and the decreasing sedation level to the (-5) level.
Since patients receiving sedation were not included in this study, only the agitation dimension of the RASS scale was used.
|
3 months
|
Glaskow Coma Scale (GCS)
Time Frame: 3 months
|
It was developed in Scotland / Glasgow in 1974 to describe the consciousness level of patients.
The scale is widely used to assess patients' level of consciousness.
There are 3 separate sections in the scale: eye opening, verbal and motor response.
GCS is obtained by summing the points the patient gets from each section.
This score ranges from three (3) to fifteen (15).
If the GCS total score is 13-15, the patient is considered awake, between 8-12 as precoma, and below 8 as coma (Sepit, 2005).
|
3 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Yasemin ÇEKİÇ, Dr., Ankara University
- Principal Investigator: Tuba YILMAZ BULUT, Msc, Ondokuz Mayıs University
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- B.30.2.ODM.0.20.08/390
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Obstructive Pulmonary Disease
-
Spire, Inc.ResMedCompletedSevere Chronic Obstructive Pulmonary Disease | Moderate Chronic Obstructive Pulmonary DiseaseUnited States
-
Karaganda Medical UniversityCompletedChronic Obstructive Pulmonary Disease | Chronic Obstructive Pulmonary Disease Moderate | Chronic Obstructive Pulmonary Disease SevereKazakhstan
-
Randall DebattistaUniversity of Malta, Faculty of Health SciencesNot yet recruitingChronic Obstructive Pulmonary Disease Moderate | Acute Exacerbation of COPD | Chronic Obstructive Pulmonary Disease Severe
-
Cukurova UniversityCompletedAnesthesia | Chronic Obstructive Pulmonary Disease Moderate | Lungcancer | Chronic Obstructive Pulmonary Disease Severe | Chronic Obstructive Pulmonary Disease MildTurkey
-
National Taipei University of Nursing and Health...TerminatedChronic Pulmonary Disease | Chronic Obstructive Pulmonary Disease Exacerbation | Chronic Obstructive Pulmonary Disease With ExacerbationTaiwan
-
Taipei Medical UniversityUnknownChronic Obstructive Pulmonary Disease Severe | Chronic Obstructive Pulmonary Disease End StageTaiwan
-
Kırıkkale UniversityRecruitingCOPD (Chronic Obstructive Pulmonary Disease)Turkey
-
Hopital FochAir Liquide SARecruitingChronic Obstructive Pulmonary Disease SevereFrance
-
Fundación para la Investigación del Hospital Clínico...Not yet recruitingCOPD, Chronic Obstructive Pulmonary DiseaseSpain
-
Canandaigua VA Medical CenterRecruitingChronic Obstructive Pulmonary Disease ModerateUnited States
Clinical Trials on Behavioral
-
Summa Health SystemCompletedHypertension | Diabetes Mellitus | Pulmonary Disease, Chronic Obstructive | Osteoarthritis | Atrial Fibrillation | Osteoporosis | Coronary Arteriosclerosis | Cerebrovascular Accident | Heart Failure, Congestive
-
Roswell Park Cancer InstituteCompletedColorectal Cancer | Healthy, no Evidence of DiseaseUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI); National Heart, Lung, and Blood Institute...Active, not recruitingHealthy SubjectUnited States
-
Mayo ClinicJames and Esther King Biomedical Research ProgramCompletedfor Cigarette Smoking and Binge Drinking CessationUnited States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI); University of RochesterRecruiting
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedProstate CarcinomaUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)Enrolling by invitationHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid NeoplasmUnited States
-
Jonsson Comprehensive Cancer CenterCompletedCancer Survivor | Stage I Breast Cancer AJCC v7 | Stage IA Breast Cancer AJCC v7 | Stage IB Breast Cancer AJCC v7 | Stage II Breast Cancer AJCC v6 and v7 | Stage IIA Breast Cancer AJCC v6 and v7 | Stage IIB Breast Cancer AJCC v6 and v7 | Stage IIIA Breast Cancer AJCC v7 | Stage 0 Breast Cancer AJCC...United States
-
Consorci Sanitari de TerrassaRecruitingCancer | Cognitive ImpairmentSpain
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingDiabetes Mellitus | Obesity-Related Malignant NeoplasmUnited States